Synthetic resins or natural rubbers -- part of the class 520 ser – Synthetic resins – Mixing of two or more solid polymers; mixing of solid...
Patent
1991-08-06
1993-08-31
Marquis, Melvyn I.
Synthetic resins or natural rubbers -- part of the class 520 ser
Synthetic resins
Mixing of two or more solid polymers; mixing of solid...
525 58, 525 59, 525 61, 525931, 525937, 525941, 524 52, 524 54, 524 57, 524925, 604 20, 607149, C08G 6348
Patent
active
052409953
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to adhesive compositions. More particularly, this invention relates to adhesives for use as in-line contact adhesives for iontophoretic agent delivery devices. Still more particularly, but without limitation thereto, this invention relates to adhesives which permit the passage therethrough of therapeutic agents and electrolytes, especially water soluble and ionized agents and electrolytes.
BACKGROUND ART
Iontophoresis, according to Dorland3 s Illustrated Medical Dictionary, is defined to be "the introduction, by means of electric current, of ions of soluble salts into the tissues of the body for therapeutic purposes." Iontophoretic devices have been known since the early 1900's. British patent specification No. 410,009 (1934) describes an iontophoretic device which overcame one of the disadvantages of such early devices known to the art at that time, namely the requirement of a special low tension (low voltage) source of current which meant that the patient needed to be immobilized near such source. The device of that British specification was made by forming a galvanic cell from the electrodes and the material containing the medicament or drug to be delivered transdermally. The galvanic cell produced the current necessary for iontophoretically delivering the medicament. This ambulatory device thus permitted iontophoretic drug delivery with substantially less interference with the patient's daily activities.
More recently, a number of U.S. patents have issued in the iontophoresis field, indicating a renewed interest in this mode of drug delivery. For example, U.S. Pat. No. 3,991,755 issued to Vernon et al; U.S. Pat. No. 4,141,359 issued to Jacobsen et al; U.S. Pat. No. 4,398,545 issued to Wilson; and U.S. Pat. No. 4,250,878 issued to Jacobsen disclose examples of iontophoretic devices and some applications thereof. The iontophoresis process has been found to be useful in the transdermal administration of medicaments or drugs including lidocaine hydrochloride, hydrocortisone, fluoride, penicillin, dexamethasone sodium phosphate, insulin and many other drugs. Perhaps the most common use of iontophoresis is in diagnosing cystic fibrosis by delivering pilocarpine salts iontophoretically. The pilocarpine stimulates sweat production; the sweat is collected and analyzed for its chloride content to detect the presence of the disease.
In presently known iontophoretic devices, at least two electrodes are used. Both of these electrodes are disposed so as to be in intimate electrical contact with some portion of the skin of the body. One electrode, called the active or donor electrode, is the electrode from which the ionic substance, medicament, drug precursor or drug is delivered into the body by iontophoresis. The other electrode, called the counter or return electrode, serves to close the electrical circuit through the body. In conjunction with the patient's skin contacted by the electrodes, the circuit is completed by connection of the electrodes to a source of electrical energy, e.g., a battery. For example, if the ionic substance to be delivered into the body is positively charged (i.e., a cation), then the anode will be the active electrode and the cathode will serve to complete the circuit. If the ionic substance to be delivered is negatively charged (i.e., an anion), then the cathode will be the active electrode and the anode will be the counter electrode.
Alternatively, both the anode and cathode may be used to deliver drugs of opposite charge into the body. In such a case, both electrodes are considered to be active or donor electrodes. For example, the anode can deliver a positively charged ionic substance into the body while the cathode can deliver a negatively charged ionic substance into the body.
It is also known that iontophoretic delivery devices can be used to deliver an uncharged drug or agent into the body. This is accomplished by a process called electroosmosis. Electroosmosis is the volume flow of a liquid (e.g., a liquid containing the uncharged drug o
REFERENCES:
patent: 2624890 (1953-06-01), Leader
patent: 2997399 (1961-08-01), Eberhard et al.
patent: 3475363 (1969-10-01), Gander
patent: 3564078 (1971-02-01), Wicker et al.
patent: 3574153 (1971-04-01), Sirota
patent: 3575911 (1971-04-01), Peterson
patent: 3975350 (1976-08-01), Hudgin et al.
patent: 4008721 (1977-02-01), Burton
patent: 4082705 (1978-04-01), Beede et al.
patent: 4140115 (1979-02-01), Schonfeld
patent: 4141359 (1979-02-01), Jacobsen et al.
patent: 4170612 (1979-10-01), Pastor et al.
patent: 4181635 (1980-01-01), Takamatsu et al.
patent: 4226915 (1980-10-01), Iijima et al.
patent: 4253460 (1981-03-01), Chen et al.
patent: 4273135 (1981-06-01), Larimore et al.
patent: 4274420 (1981-06-01), Hymes
patent: 4356819 (1982-11-01), Potaczek
patent: 4391278 (1983-07-01), Cahalan et al.
patent: 4393080 (1983-07-01), Pawelchak et al.
patent: 4393150 (1983-07-01), Kresner
patent: 4456741 (1984-06-01), Ames
patent: 4460371 (1984-07-01), Abber
patent: 4474570 (1984-10-01), Ariura et al.
patent: 4564010 (1986-01-01), Coughlan et al.
patent: 4588762 (1986-05-01), Mruk et al.
patent: 4655767 (1987-04-01), Woodward et al.
patent: 4702732 (1987-10-01), Powers et al.
patent: 4777954 (1988-10-01), Keusch et al.
patent: 4780411 (1988-10-01), Piejko et al.
patent: 4798876 (1989-01-01), Gould et al.
patent: 4820263 (1989-04-01), Spevak et al.
patent: 4830776 (1989-05-01), Thompson
patent: 4860754 (1989-08-01), Sharik et al.
patent: 5080646 (1992-01-01), Theeuwes et al.
Patent Abstracts of Japan, vol. 9, No. 278 (C-312)(2001)(Nov. 6, 1985) and JP, A,60123416 (Nitto Denki Kogyo K.K.) (Jul. 2, 1985) SEE Ohtsuka et al. above (w/translation).
Chemical Abstracts, vol. 86, No. 19 (May 9, 1977) J. F. MacDonald: "Pharmacology of dopamine receptors in the central nervous system of Planorbis corneus," PCT, International Search Report, PCT/US90/00727, (Jul. 20, 1990) EPO, The Hague.
PCT, International Preliminary Examination Report, PCT/US90/00727, (Mar. 22, 1991) EPO, Munich.
Gyory J. Richard
Haak Ronald P.
Lew Patrick J.
Theeuwes Felix
ALZA Corporation
Gulakowski Randy
Mandell Edward L.
Marquis Melvyn I.
Miller D. Byron
LandOfFree
Electrotransport adhesive does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Electrotransport adhesive, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Electrotransport adhesive will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2297983